Ignite Creation Date:
2025-12-24 @ 3:39 PM
Ignite Modification Date:
2026-02-03 @ 5:59 AM
Study NCT ID:
NCT01741792
Status:
COMPLETED
Last Update Posted:
2017-01-06
First Post:
2012-11-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Sponsor:
Amgen Research (Munich) GmbH
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Diffuse Large B-cell Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Relapsed DLBCL | View |
| None | Refractory DLBCL | View |
| None | adult DLBCL | View |
| None | Lymphoma | View |
| None | Non-Hodgkin Lymphoma | View |
| None | Lymphatic diseases | View |
| None | Lymphoproliferative disorders | View |
| None | bispecific antibody | View |
| None | anti-CD19 | View |
| None | Immunotherapeutic treatment | View |
| None | Immunoproliferative disorders | View |